reports
NETSOL Technologies secures landmark multi-million-dollar contract wit...
NETSOL Technologies secures landmark multi-million-dollar contract with leading Australian auto captive of Japanese origin The customer selected NETSOL after a highly competitive evaluation process, during which Transcend Finance emerged as the superior solution, displacing an industry competitor ENCINO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the signing of a multi-million-dollar contract with a...
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavap...
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic ...
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S...
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting expected by end of September THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that the Company has submitted additional clini...
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin...
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain - (NeuPSIG) 2025. The findings highlight the relevance of inhibiting pilavapadin’s novel target, AAK1, ...
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral ...
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada. Presentation details: Poster #53: ...
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Fai...
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of...
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Confer...
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8 at 3:00 p.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals...
NETSOL Chosen by Sonic Automotive to Power Next-Gen Digital Retail Exp...
NETSOL Chosen by Sonic Automotive to Power Next-Gen Digital Retail Experience ENCINO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced its selection by Sonic Automotive, Inc. (NYSE: SAH), a Fortune 500 automotive and powersports dealership group, to lead a discovery engagement focused on defining the requirements and roadmap for a next-generation omnichannel digital retail platform powered by NETSOL’s Transc...
Clearside Biomedical Announces Multiple Presentations on Suprachoroida...
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress - Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad - ALPHARETTA, Ga., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the...
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results ...
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Na...
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Pri...
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq’s listing qualifications staff has determined that the closing bid price of the Company’s common stock has been at $1.00 per share or greater for ten consecutive business days and that, accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). This update was previously disclosed in the Company’s Current Report on Form 8-K filed on July 28, 2025. Ab...
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Result...
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s websi...
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Trea...
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has...
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neurop...
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of care will be presented at the 7th Annual Meetin...
Chinese leasing company goes live with Transcend Finance in Indonesia
Chinese leasing company goes live with Transcend Finance in Indonesia ENCINO, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the successful go-live of its Transcend Finance platform for a leading Chinese leasing company, marking the customer's official launch of operations in the Indonesian market. The customer, known for offering a wide range of leasing solutions across sectors including equipment leasin...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives ...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations - ALPHARETTA, G...
NETSOL Technologies China Signs Strategic Agreement at the SCO Summit ...
NETSOL Technologies China Signs Strategic Agreement at the SCO Summit 2025 ENCINO, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, participated at the Shanghai Cooperation Organization (SCO) Summit in Tianjin, China this past week on July 11, 2025, where it signed a strategic cooperation agreement with Tianjin Binhai Smart Group Co., Ltd. and the Dongjiang Free Trade Port Zone Government. The partnership will focus on t...
NETSOL Technologies Appoints Ian Smith to its Board of Directors
NETSOL Technologies Appoints Ian Smith to its Board of Directors ENCINO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the appointment of Ian Smith to its Board of Directors, effective July 1, 2025. Mr. Smith brings with him over three decades of global leadership experience in financial services, with a proven track record in automotive finance, digital transformation and strategic growth. Most notably,...
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Import...
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) annou...
Lexicon to Present Data at the 85th Scientific Sessions of the America...
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.